Phase 1 Myeloma Trial, Recruiting NCT06623630 Sponsor: Washington University School of Medicine Condition: Myeloma
Back to Myeloma

Phase 1 Myeloma Trial, Recruiting

NCT06623630
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with multiple myeloma, confirmed through a tissue test (biopsy).
  • Your kidneys are not working at full capacity — specifically, your kidney filtering rate (eGFR) is below 45.
  • You are 18 years of age or older.
  • You are generally able to carry out normal daily activities with little to no limitation (confirm with trial site).
  • You qualify for a specific cancer cell therapy called cilta-cel based on standard medical guidelines.
  • Your white blood cell (neutrophil) count meets a minimum level; if it is low due to recent treatment, you may be re-tested during the screening period to check again.
  • If you have previously had a stem cell transplant using your own cells, the transplant must have contained a sufficient number of stem cells (confirm with trial site for specific numbers).
  • You must have enough of your own stored stem cells available, in case they are needed during treatment.
  • If you are a woman who could become pregnant, or a man, you must agree to use reliable birth control throughout the study; you must tell your doctor immediately if pregnancy is suspected.
  • You are willing and able to read and sign a consent form agreeing to take part; a legal representative may do this on your behalf if needed.

Who may not be able to join:

  • You have another cancer (past or current) that could affect the safety of the treatment or make results harder to measure (confirm with trial site).
  • You are currently taking part in another clinical trial involving an experimental treatment.
  • You have an uncontrolled serious illness, such as an active infection, severe heart failure, unstable chest pain, or an unstable irregular heartbeat; heart function must meet a minimum standard to be eligible (confirm with trial site).
  • You are currently pregnant or breastfeeding; women who could become pregnant must have a negative pregnancy test within 14 days of joining.
  • You are HIV-positive and have not had an undetectable viral load for at least 6 months on effective HIV treatment.
  • You have chronic hepatitis B virus (HBV) and your viral load is still detectable, even on suppressive treatment.
  • You have a history of hepatitis C virus (HCV) that has not been cured, or your viral load is still detectable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michael J Slade, M.D., MSCI, Washington University School of Medicine

Phone: 314-454-8304

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
4 December 2024
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of dose-limiting toxicities (DLTs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov